Schistosomiasis Clinical Trial
Official title:
Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas
The study intends to examine the association between schistosomiasis seropositivity and adverse pregnancy outcomes. It aims at the verification of the hypothesis that in pregnant women originating from endemic areas for schistosomiasis, positive serology is associated with reduced Infant birth weight.
Schistosomiasis is a widespread helminthic infection, with an estimated 249 million people in 78 countries requiring preventive treatment each year. This infection has a significant association with morbidity worldwide. Earlier studies performed in endemic Areas showed that the reproductive tract was affected in more than 60% of the women who excreted S. haematobium ova in urine. Transplacental transmission has not been observed, but schistosomiasis of the pregnant uterus has been reported and placental schistosomiasis has been associated with stillbirth. Placental schistosomiasis (i.e. detection of schistosomiasis eggs in placental tissue) has been reported occasionally. Schistosomiasis has been postulated to be associated with premature delivery and low birth weight; however, existing data are inconsistent. Migration to the European Union was estimated at 1.7 million people in 2012. Migrants were predominantly from Africa and Asia. In these areas schistosomiasis has an estimated prevalence of 10-20%. While a large number of migrants from schistosomiasis-endemic areas enter Europe and receive Access to health care, many of them are unaware of helminthic infections they may have been exposed to, and their potential outcomes. Treatment of schistosomiasis during pregnancy is a matter of debate. The German society for tropical medicine recommends treatment with praziquantel only after the completion of pregnancy. Conversely, the South African Medicines Formulary suggests that pregnant women should be offered treatment individually and that they should not necessarily be excluded during treatment campaigns. By quantifying the effects of Schistosoma infection on pregnancy outcomes this study will help clinicians in deciding on the question of treatment during pregnancy. The aim of the study is to examine the association of maternal schistosomiasis on adverse birth outcomes (as defined by low birth weight, premature delivery or stillbirth) in migrants to Europe from schistosomiasis endemic areas. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04115072 -
Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05999825 -
Sm-p80 Schistosomiasis Challenge Study
|
Phase 2 | |
| Completed |
NCT00463931 -
Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana
|
N/A | |
| Completed |
NCT00215267 -
The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda
|
N/A | |
| Completed |
NCT00276224 -
Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
|
N/A | |
| Completed |
NCT03845140 -
L-PZQ ODT in Schistosoma Infected Children
|
Phase 3 | |
| Completed |
NCT01512277 -
Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis
|
Phase 1 | |
| Active, not recruiting |
NCT03910972 -
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT05085470 -
Repeated Controlled Human Schistosoma Mansoni Infection
|
N/A | |
| Completed |
NCT02755324 -
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
|
N/A | |
| Recruiting |
NCT05868005 -
Delivering a Multi-disease Screening Tool to Migrant Populations
|
N/A | |
| Active, not recruiting |
NCT01869465 -
Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis
|
N/A | |
| Completed |
NCT01553552 -
Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal
|
N/A | |
| Recruiting |
NCT04589390 -
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
|
Phase 2 | |
| Completed |
NCT02868385 -
Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)
|
Phase 3 | |
| Recruiting |
NCT05762393 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
|
Phase 1 | |
| Not yet recruiting |
NCT06182176 -
Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control
|
N/A | |
| Completed |
NCT05292391 -
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT03110757 -
A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults
|
Phase 1 | |
| Completed |
NCT01154049 -
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
|
Phase 1 |